Grants and Contracts Details
| Status | Active |
|---|---|
| Effective start/end date | 9/21/23 → 9/21/25 |
Funding
- Viewpoint Molecular Targeting Incorporated: $32,207.00
23-MEL-13-VMT-PMC (VMT01-T101): A Phase I/IIa, First-In-Human, Multi-Center Dose Escalation and Dose Expansion Study of [203/212Pb]VMT01 Receptor-Targeted, Image-Guided Alpha-Particle Therapy in Patients With Previously Treated Unresectable or Metastatic
- Arays, Ruta (PI)